EIF2A and acute myeloid leukemia: Furthermore, AML patients with lower levels of p-eIF2α exhibit higher frequency of relapse compared with those with higher p-eIF2α [37], further supporting the notion that triggering p-eIF2α expression may have therapeutic benefit.